Matthew Vincent Dolan - 08 Mar 2023 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
SVP Corporate Strategy-Develop
Signature
By: Jereme Sylvain For: Matthew V Dolan
Issuer symbol
DXCM
Transactions as of
08 Mar 2023
Net transactions value
+$21.77
Form type
4
Filing time
10 Mar 2023, 15:00:44 UTC
Previous filing
06 Mar 2023
Next filing
14 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $21.77 +21,769 +82% $0.001000* 48,305 08 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2 Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.